Endocrine Society GUIDELINES Bundle (free trial)

Condenital Adrenal Hyperplasia

Endocrine Society GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: http://eguideline.guidelinecentral.com/i/302964

Contents of this Issue

Navigation

Page 2 of 17

Diagnosis 3 Newborn Screening ➤ Endocrine Society (ES) recommends that all newborn screening programs incorporate screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency. (1|⊕⊕⊕ ) ➤ ES recommends that first-tier screens use 17-hydroxyprogesterone assays standardized to a common technology with norms stratified by gestational age. (1|⊕⊕⊕ ) Technical remark: Clinicians should be aware that immunoassays are still in use and remain a source of false-positive results. Specificity may be improved with organic extraction to remove cross-reacting substances. ➤ ES recommends that screening laboratories employ a second-tier screen by liquid chromatography–tandem mass spectrometry in preference to all other methods (e.g., genotyping) to improve the positive predictive value of congenital adrenal hyperplasia screening. (1|⊕⊕ ) Technical remark: Laboratories utilizing liquid chromatography–tandem mass spectrometry should participate in an appropriate quality assurance program. Additionally, clinicians should realize that immunoassays lead to more false-positive results. Thus, if laboratory resources do not include liquid chromatography–tandem mass spectrometry, a cosyntropin stimulation test should be performed to confirm diagnosis prior to initiation of corticosteroid treatment. Diagnosis of Congenital Adrenal Hyperplasia ➤ In infants with positive newborn screens for congenital adrenal hyperplasia, ES recommends referral to pediatric endocrinologists (if regionally available) and evaluation by cosyntropin stimulation testing as needed. (1|⊕⊕⊕ ) ➤ In symptomatic individuals past infancy, ES recommends screening with an early-morning (before 8 AM) baseline serum 17-hydroxyprogesterone measurement by liquid chromatography–tandem mass spectrometry. (1|⊕⊕⊕ ) ➤ In individuals with borderline 17-hydroxyprogesterone levels, ES recommends obtaining a complete adrenocortical profile after a cosyntropin stimulation test to differentiate 21-hydroxylase deficiency from other enzyme defects. (1|⊕⊕⊕ ) ➤ In individuals with congenital adrenal hyperplasia, ES suggests genotyping only when results of the adrenocortical profile after a cosyntropin stimulation test are equivocal, or cosyntropin stimulation cannot be accurately performed (i.e., patient receiving glucocorticoid), or for purposes of genetic counseling. (2|⊕⊕⊕ ) Technical remark: Genotyping at least one parent aids in the interpretation of genetic test results because of the complexity of the CYP21A2 locus.

Articles in this issue

Archives of this issue

view archives of Endocrine Society GUIDELINES Bundle (free trial) - Condenital Adrenal Hyperplasia